KFA
WST icon

Krane Funds Advisors’s West Pharmaceutical WST Stock Holding History

Krane Funds Advisors’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-983
Closed -$404K – 362
2022
Q1 		$404K Buy
983
+154
+19% +$60.3K 0.02% 224
2021
Q4 		$389K Sell
829
-91
-10% -$39.2K 0.01% 189
2021
Q3 		$391K Sell
920
-671
-42% -$283K 0.01% 232
2021
Q2 		$571K Sell
1,591
-12
-0.7% -$3.96K 0.02% 146
2021
Q1 		$452K Buy
1,603
+316
+25% +$90.4K 0.02% 195
2020
Q4 		$365K Sell
1,287
-148
-10% -$41.5K 0.01% 159
2020
Q3 		$394K Sell
1,435
-407
-22% -$108K 0.02% 133
2020
Q2 		$418K Sell
1,842
-1,424
-44% -$280K 0.03% 99
2020
Q1 		$497K Sell
3,266
-340
-9% -$52.3K 0.03% 88
2019
Q4 		$542K Buy
3,606
+69
+2% +$10K 0.04% 143
2019
Q3 		$502K Buy
3,537
+3,330
+1,609% +$458K 0.04% 180
2019
Q2 		$26K Buy
+207
New +$24.4K ﹤0.01% 134

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Krane Funds Advisors's WST Position: Q2 2022 in Review

Krane Funds Advisors sold out of West Pharmaceutical (WST) in Q2 2022, closing a stake of 983 shares — an estimated $404K sold.

Krane Funds Advisors first reported a position in WST in Q2 2019 and held it in 12 quarters. The position peaked at $571K in Q2 2021. 655 funds tracked by Wall St. Rank hold WST as of Q2 2022.

  • Krane Funds Advisors reported no remaining West Pharmaceutical position as of Q2 2022 after selling out during the quarter.
  • Krane Funds Advisors sold 983 West Pharmaceutical shares in Q2 2022, an estimated $404K.
  • Krane Funds Advisors first reported a position in West Pharmaceutical in Q2 2019 and held it in 12 quarters.
  • Krane Funds Advisors's West Pharmaceutical position peaked at $571K in Q2 2021.
  • 655 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2022.

Based on Krane Funds Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.